Jay Bradner

President at Novartis Institutes for BioMedical Research, Inc.

Jay Bradner

Jay Bradner

President at Novartis Institutes for BioMedical Research, Inc.

Overview
Career Highlights

Novartis Institutes for BioMedical Research, Inc.
Acetylon Pharmaceuticals, Inc.
C4 Therapeutics, Inc.

RelSci Relationships

4283

Number of Boards

10

Birthday

1972

Age

49

Number of Awards

4

Relationships
RelSci Relationships are individuals Jay Bradner likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief, Division of Hematologic Neoplasia at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Novartis AG

Relationship likelihood: Strong

Chief Executive Officer at Novartis AG

Relationship likelihood: Strong

Co-Founder at C4 Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer, Sandoz at Novartis AG

Relationship likelihood: Strong

Division Head, Alcon at Novartis AG

Relationship likelihood: Strong

Former Director-Chemistry Platform at The Massachusetts General Hospital

Relationship likelihood: Strong

Director, President, Chief Executive Officer, Chief Financial Officer, Treasurer & Secretary at Leap Therapeutics, Inc.

Relationship likelihood: Strong

Chief People & Organization Officer at Novartis AG

Relationship likelihood: Strong

Chief Medical Officer at Novartis AG

Relationship likelihood: Strong

Paths to Jay Bradner
Potential Connections via
Relationship Science
You
Jay Bradner
President at Novartis Institutes for BioMedical Research, Inc.
Education
MD
Class of 1999

The Pritzker School of Medicine is the M.D. granting unit of the Biological Sciences Division of the University of Chicago. It is located on the University's main campus in the historic Hyde Park neighborhood of Chicago, and matriculated its first class in 1927.As one of the most selective medical schools in the United States, it is currently ranked 10th among research universities for medical education by the US News & World Report.

MMS

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

AB

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

Memberships
Member
Current

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Member
Current

American Society for Clinical Investigation is an American private company located in Ann Arbor, MI, that provides clinical investigation services.

Member
Prior

American Chemical Society engages as a scientific society which supports scientific inquiry in the field of Chemistry. The company was founded in 1876 and is headquartered in Washington, DC.

Career History
Scientific Founder
2008 - ?

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

Co-Founder
2008 - Prior

TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA.

Founder
2011 - Prior

Tensha Therapeutics, Inc. develops small molecule bromodomain inhibitors. The firm’s product is used to treat cancer and other serious disorders. The company was founded by James Bradner in 2011 and is headquartered in Cambridge, MA.

Boards & Committees
Member, Executive Committee
2016 - Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Director
2008 - Current

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

Chairman, Board of Directors
Current

Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA.

Member, Executive Committee
Prior - 2016

The American Society of Hematology 's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Board Member
2012 - 2016

The Leukemia & Lymphoma Society's New York City Chapter was founded to serve residents who have been touched by one of the blood cancers: leukemia, lymphoma and myeloma. The chapter serves the five boroughs of New York City.

Member, Scientific Advisory Council
Prior

CureSearch for Children's Cancer dedicates private funds for childhood cancer research for the Children's Oncology Group. Its Children's Oncology Group has a network of more than 5,000 physicians, nurses, and scientists whose collaboration, research, and care have turned childhood cancer from a virtually incurable disease to one with an overall 78% cure rate. The company was founded by Dr. G. Denman Hammond and is headquartered in Bethesda, MD.

Investments
Details Hidden

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Details Hidden

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Details Hidden

Tensha Therapeutics, Inc. develops small molecule bromodomain inhibitors. The firm’s product is used to treat cancer and other serious disorders. The company was founded by James Bradner in 2011 and is headquartered in Cambridge, MA.

Awards & Honors
Damon Runyon-Rachleff Innovation Award
Smith Family Award for Excellence in Biomedical Research
HMS Distinguished Excellence in Teaching Award
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jay Bradner. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jay Bradner's profile does not indicate a business or promotional relationship of any kind between RelSci and Jay Bradner.